Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.

PubWeight™: 1.15‹?› | Rank: Top 10%

🔗 View Article (PMID 11841453)

Published in Br J Haematol on February 01, 2002

Authors

Silverio Perrotta1, Franco Locatelli, Angela La Manna, Lucia Cennamo, Piero De Stefano, Bruno Nobili

Author Affiliations

1: Department of Paediatrics, 2nd University of Naples, Naples, Italy. silverio.perrotta@unina2.it

Articles citing this

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06

CD20-mediated apoptosis: signalling through lipid rafts. Immunology (2002) 1.69

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis (2006) 1.59

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol (2004) 1.37

Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wien Klin Wochenschr (2008) 1.34

B cell depletion in autoimmune disease. Arthritis Res Ther (2003) 1.03

Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol (2004) 1.00

B cells in autoimmune diabetes. Rev Diabet Stud (2005) 0.93

Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis (2003) 0.87

Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission. Clin Rheumatol (2008) 0.86

Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr (2007) 0.84

SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int (2005) 0.84

Anti-CD79 antibody induces B cell anergy that protects against autoimmunity. J Immunol (2014) 0.81

Precautions surrounding blood transfusion in autoimmune haemolytic anaemias are overestimated. Blood Transfus (2015) 0.77

Use of rituximab in two unusual antibody-mediated autoimmune disorders. J R Soc Med (2005) 0.75

Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: the first case report from Indonesia. Clin Rheumatol (2008) 0.75

Articles by these authors

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59

Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood (2010) 4.17

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88

Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut (2011) 3.81

Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res (2007) 3.19

Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica (2005) 3.11

Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol (2004) 2.81

Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood (2007) 2.55

Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood (2009) 2.51

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45

Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol (2007) 2.38

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35

Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood (2008) 2.34

Febrile urinary tract infections in young children: recommendations for the diagnosis, treatment and follow-up. Acta Paediatr (2012) 2.34

Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica (2007) 2.23

Atypical features of familial hemophagocytic lymphohistiocytosis. Blood (2004) 2.21

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood (2009) 2.15

Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood (2013) 2.12

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol (2005) 2.10

Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood (2009) 2.06

An infant with hypercalcemia: questions. Pediatr Nephrol (2013) 2.03

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood (2008) 1.96

Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91

Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood (2011) 1.78

Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica (2008) 1.78

Mesenchymal stromal cells. Ann N Y Acad Sci (2009) 1.76

Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. N Engl J Med (2004) 1.72

Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica (2010) 1.68

Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood (2007) 1.67

Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol (2005) 1.64

Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood (2007) 1.61

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood (2003) 1.58

Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow Transplant (2005) 1.58

Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.58

Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood (2010) 1.56

Ethical reappraisal of 15 years of cord-blood transplantation. Lancet (2003) 1.55

A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood (2005) 1.54

Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy (2011) 1.54

Long-term evolution of renal damage associated with unilateral vesicoureteral reflux. J Urol (2007) 1.52

Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica (2005) 1.51

Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica (2003) 1.51

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood (2002) 1.50

Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood (2003) 1.49

Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev (2008) 1.47

SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood (2005) 1.44

Human hepatic stellate cells are liver-resident antigen-presenting cells. Hepatology (2011) 1.42

Congenital aggressive variant of Langerhans cells histiocytosis with CD56+/E-Cadherin- phenotype. Pediatr Blood Cancer (2009) 1.42

Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol (2003) 1.42

Molecular basis of Diamond-Blackfan anemia: new findings from the Italian registry and a review of the literature. Haematologica (2004) 1.41

A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood (2003) 1.40

Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica (2005) 1.40

Familial haemophagocytic lymphohistiocytosis: survival of a premature twin with immuno-chemotherapy and bone marrow transplantation from an HLA-identical unrelated donor. Acta Paediatr (2005) 1.39

Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood (2012) 1.37

Systematic identification of edited microRNAs in the human brain. Genome Res (2012) 1.35

Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood (2002) 1.34

Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol (2013) 1.31

Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood (2013) 1.29

CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood (2013) 1.28

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood (2002) 1.28

Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster. Blood (2005) 1.26

Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. J Clin Oncol (2010) 1.25

Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br J Haematol (2005) 1.25

Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood (2007) 1.23

Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol (2007) 1.22

Polyomavirus BK-specific immunity after kidney transplantation. Transplantation (2004) 1.22

Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood (2005) 1.20

A-to-I RNA editing: the "ADAR" side of human cancer. Semin Cell Dev Biol (2011) 1.19

Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant (2007) 1.19

Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci (2005) 1.18

Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol (2011) 1.18

Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant (2007) 1.17

Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing. Cancer Res (2011) 1.16

Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol (2009) 1.16

Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment. Blood (2009) 1.15

Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood (2005) 1.14

Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des (2013) 1.13

Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica (2008) 1.12

Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood (2011) 1.12

Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C-/- umbilical cord blood. J Immunol (2014) 1.12

GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood (2005) 1.11

Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica (2009) 1.10

Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica (2010) 1.09

ADARs: allies or enemies? The importance of A-to-I RNA editing in human disease: from cancer to HIV-1. Biol Rev Camb Philos Soc (2011) 1.09

Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol (2008) 1.09

Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood (2008) 1.07

Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype. Eur J Haematol (2005) 1.07

Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion (2010) 1.06

A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group. Br J Haematol (2002) 1.06

Adolescents with cancer in Italy: entry into the national cooperative paediatric oncology group AIEOP trials. Eur J Cancer (2009) 1.06

Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease. Blood (2004) 1.05

Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood (2010) 1.05

Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res (2012) 1.05

Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood (2006) 1.04